[HTML][HTML] Adherence to targeted oral anticancer medications
DM Geynisman, KE Wickersham - Discovery medicine, 2013 - ncbi.nlm.nih.gov
The use of targeted oral anticancer medications (OAMs) is becoming increasingly prevalent
in cancer care. Approximately 25–30% of the oncology drug pipeline involves oral agents …
in cancer care. Approximately 25–30% of the oncology drug pipeline involves oral agents …
Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses
V Du Pont, RK Plemper, MJ Schnell - Current opinion in virology, 2019 - Elsevier
Rabies virus (RABV) constitutes a major social and economic burden associated with 60
000 deaths annually worldwide. Although pre-exposure and post-exposure treatment …
000 deaths annually worldwide. Although pre-exposure and post-exposure treatment …
Prophylactic treatment of dacomitinib‐induced skin toxicities in epidermal growth factor receptor‐mutated non–small‐cell lung cancer: A multicenter, Phase II trial
M Iwasaku, J Uchino, K Chibana, S Tanzawa… - Cancer …, 2023 - Wiley Online Library
Background Dacomitinib significantly improves progression‐free survival and overall
survival (OS) compared with gefitinib in patients with non–small‐cell lung cancer (NSCLC) …
survival (OS) compared with gefitinib in patients with non–small‐cell lung cancer (NSCLC) …
Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non–Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup …
K Hotta, J Sasaki, S Saeki, N Takigawa, K Katsui… - Clinical Lung Cancer, 2016 - Elsevier
Herein, we describe an ongoing phase II trial in patients with locally advanced non–small-
cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR). Patients …
cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR). Patients …
[HTML][HTML] Opportunities and risks of host-targeting antiviral strategies for hepatitis C
G Gerold, T Pietschmann - Current hepatitis reports, 2013 - Springer
Hepatitis C virus (HCV) infects more than 2% of the world population with highest
prevalence in parts of Africa and Asia. Past standard of care using interferon α and ribavirin …
prevalence in parts of Africa and Asia. Past standard of care using interferon α and ribavirin …
回溯性分析Erlotinib 的藥物交互作用
廖晨妤 - 2012 - tdr.lib.ntu.edu.tw
一, 背景: 過往研究顯示, 發現僅有少數的文獻探討erlotinib 的藥物交互作用, 然而,
在非小細胞肺癌的治療上卻愈趨重要. 若能區辨藥物種類的影響, 則能提升療效與降低副作用 …
在非小細胞肺癌的治療上卻愈趨重要. 若能區辨藥物種類的影響, 則能提升療效與降低副作用 …